Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition.

ABSTRACT:

SUBMITTER: de Silva M 

PROVIDER: S-EPMC7214900 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature